Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04524689
Title Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Sanofi
Indications

lung non-squamous non-small cell carcinoma

Therapies

Carboplatin + Pembrolizumab + Pemetrexed Disodium + SAR408701

Cisplatin + Pemetrexed Disodium + SAR408701

Carboplatin + Pembrolizumab + SAR408701

Pembrolizumab + SAR408701

Cisplatin + Pembrolizumab + SAR408701

Age Groups: adult | senior
Covered Countries USA | FRA | ESP

Additional content available in CKB BOOST